Why the study?
Does colchicine added to standard medical therapy reduce major adverse cardiac events in patients with acute coronary syndrome?
Does colchicine added to standard medical therapy reduce major adverse cardiac events in patients with acute coronary syndrome?
Adding colchicine to standard medical therapy in ACS patients significantly reduces MACE and improves survival over a 6-month period.
Answers are grounded in this paper and cite their sources.
Supports colchicine addition in ACS now; strengthens low-certainty evidence from 9 prior studies.
The addition of colchicine to standard medical therapy in ACS patients significantly reduces MACE occurrence and improves survival rate over the time.
No takes yet. Share an insight, caveat, or question.
Akrami et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: